Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An announcement from Actinogen Medical ( (AU:ACW) ) is now available.
Actinogen Medical held its 2025 Annual General Meeting in Sydney, where the Chair and CEO presented updates on their clinical trials and strategic direction. The company is advancing its XanaMIA Phase 2b/3 trial for Alzheimer’s disease, with full enrollment expected by the end of 2025 and initial results in early 2026. The XanaCIDD trial for depression showed significant benefits, reinforcing the potential of Xanamem in treating cognitive and depressive symptoms. These developments position Actinogen as a promising player in the biotechnology industry, with potential implications for stakeholders in terms of future treatment options and market growth.
More about Actinogen Medical
Actinogen Medical is an ASX-listed biotechnology company focused on developing novel therapies for neurological and neuropsychiatric diseases linked to dysregulated brain cortisol. Their lead compound, Xanamem, is being developed as a treatment for Alzheimer’s Disease, Depression, and potentially Fragile X Syndrome, addressing a significant unmet need for effective treatments in these areas.
Average Trading Volume: 3,723,869
Technical Sentiment Signal: Buy
Current Market Cap: A$165.3M
Learn more about ACW stock on TipRanks’ Stock Analysis page.